Financial Data and Key Metrics Changes - Acumen Pharmaceuticals ended 2025 with $116.9 million in cash and marketable securities, expected to support operations into early 2027 [15] - R&D expenses were $104.9 million in 2025, an increase attributed to manufacturing and materials for the ALTITUDE-AD trial, as well as personnel-related costs [15] - General and administrative expenses decreased to $18.9 million in 2025, primarily due to reductions in recruiting, corporate insurance, and consulting costs [15] - The company reported a net loss of $121.3 million in 2025 [16] Business Line Data and Key Metrics Changes - The lead program, sabirnetug, is in the phase II ALTITUDE-AD trial, which is investigating its efficacy against Alzheimer's disease [5] - The company expanded its pipeline with the enhanced brain delivery (EBD) partnership with JCR Pharmaceuticals, aiming to improve treatment options for Alzheimer's [6] - Positive effects on phospho-tau-181 and neurogranin levels were observed in the phase Ib INTERCEPT-AD study, supporting the potential of sabirnetug [7] Market Data and Key Metrics Changes - The Alzheimer’s disease market is seeing increased momentum, with growing evidence supporting the clinical benefits of targeting A-beta [9] - The company noted a hopeful environment for Alzheimer's patients, with advancements in blood-based biomarkers aiding in development and diagnosis [9] Company Strategy and Development Direction - Acumen is focused on executing and expanding its clinical programs, particularly the ALTITUDE-AD trial and the EBD program [5] - The company aims to read out ALTITUDE-AD results by late 2026, which will inform its broader development strategy in Alzheimer's treatment [7] - The EBD program is expected to enhance brain penetration and distribution of antibodies, potentially leading to improved safety and efficacy [6][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the success of the ALTITUDE-AD trial based on supportive imaging and biomarker data [7] - The company believes it is in a strong position to deliver differentiated treatment options for Alzheimer's patients, driven by scientific innovation [10] - Management highlighted the importance of understanding the evolving treatment landscape in Alzheimer's and the potential for improved benefit-risk profiles [10] Other Important Information - A private placement raised approximately $36 million to support the EBD program, indicating strong institutional investor confidence [16] - The company is targeting an IND filing for a clinical candidate in mid-2027 [8] Q&A Session Summary Question: How has patient retention been in the ALTITUDE-AD study? - Management reported good retention and rollover rates, consistent with other major Alzheimer's trials, indicating positive safety and tolerability [20][22] Question: What preclinical data supports the viability of EBD candidates? - Multiple candidates showed enhanced brain penetration, with 14- to 40-fold improvements in brain levels compared to native antibodies, indicating strong profiles for progression [26][27] Question: What is the rationale behind the 35 mg/kg dosing in the OLE? - The 35 mg/kg dose was selected based on saturation data from the phase I study, ensuring good target engagement without unnecessary increases in dosage [76][77] Question: What are the expectations for plaque reduction in the OLE? - Management indicated uncertainty about plaque reduction outcomes at 18 months, noting that the study aims to gather data on this aspect [56] Question: How does the EBD program improve upon existing therapies? - The EBD technology is expected to enhance distribution and efficacy of antibodies, potentially leading to better clinical outcomes compared to non-carrier-mediated antibodies [37]

Financial Data and Key Metrics Changes - Acumen Pharmaceuticals ended 2025 with $116.9 million in cash and marketable securities, expected to support operations into early 2027 [15] - R&D expenses were $104.9 million in 2025, an increase attributed to manufacturing and materials for the ALTITUDE-AD trial, as well as personnel-related costs [15] - General and administrative expenses decreased to $18.9 million in 2025, primarily due to reductions in recruiting, corporate insurance, and consulting costs [15] - The company reported a net loss of $121.3 million for 2025 [16] Business Line Data and Key Metrics Changes - The lead program, sabirnetug, is in the phase II ALTITUDE-AD trial, which is investigating its efficacy against Alzheimer's disease [5] - The EBD program, in partnership with JCR Pharmaceuticals, aims to enhance brain delivery of therapies targeting amyloid beta oligomers [6][10] Market Data and Key Metrics Changes - The Alzheimer's disease treatment market is evolving, with increasing evidence supporting the clinical benefits of targeting amyloid beta [9] - The company noted a positive sentiment in the Alzheimer's field, particularly after attending the AD/PD Conference in Denmark [8] Company Strategy and Development Direction - Acumen is focused on executing and expanding its clinical programs, particularly the ALTITUDE-AD trial and the EBD program [5] - The company aims to develop differentiated therapies for Alzheimer's patients, leveraging its scientific innovation and execution track record [10] - Plans for 2026 include reading out ALTITUDE-AD results, which will inform future development strategies [7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ALTITUDE-AD trial based on positive biomarker data from the phase I-B INTERCEPT-AD study [7] - The company believes there is ample opportunity to improve treatment options for Alzheimer's patients, emphasizing the importance of safety and efficacy [10] Other Important Information - A private placement raised approximately $36 million to support the EBD program [8] - The company is targeting an IND filing for a clinical candidate in mid-2027 [8] Q&A Session Summary Question: How has patient retention been in the ALTITUDE-AD study? - Management reported satisfaction with retention and rollover rates, indicating they are consistent with other major Alzheimer's trials [20][22] Question: What preclinical data supports the viability of EBD candidates? - Management highlighted multiple candidates showing enhanced brain penetration and low anemia risk, with promising profiles exceeding target expectations [26][70] Question: What is the rationale behind the 35 mg per kg dosing in the OLE? - The choice was based on achieving good target engagement without unnecessary increases in dosage, supported by data from the phase I study [73]

Core Insights - Acumen Pharmaceuticals is advancing its Alzheimer's disease treatment, sabirnetug (ACU193), through innovative approaches targeting soluble amyloid beta oligomers (AβOs) [1][10] Group 1: Research Findings - New research findings were presented at the International Conference on Alzheimer's and Parkinson's Diseases, focusing on enhanced brain delivery methods, novel biomarker approaches, and selective antibody development [1][2] - The company is collaborating with JCR Pharmaceuticals to improve drug penetration across the blood-brain barrier using bispecific antibodies targeting transferrin receptors [3][11] - The Phase 1 INTERCEPT-AD study showed treatment-related biomarker changes, indicating sabirnetug's effects on key Alzheimer's biomarkers [4] Group 2: Enhanced Brain Delivery - Acumen's Enhanced Brain Delivery (EBD™) technology demonstrated increased brain exposure of sabirnetug while maintaining target engagement with AβOs [3][4] - The collaboration with JCR Pharmaceuticals utilizes the J-Brain Cargo® platform to facilitate brain uptake of therapeutics [3][11] Group 3: Biomarker Evaluation - The NULISAseq™ technology was employed to measure 127 proteins related to Alzheimer's pathology, showing strong correlations with established clinical platforms [4] - A dedicated bioanalytical database has been established to support further exploratory analyses and integration with ongoing studies [4] Group 4: Antibody Development - Acumen is developing highly selective anti-AβO antibodies, with ACU234 showing approximately 21,000-fold greater affinity for oligomers compared to monomers [5][6] - Further evaluation of ACU234 confirmed its ability to bind disease-relevant AβOs in both human brain samples and transgenic mouse models [6] Group 5: Clinical Trials - The ongoing Phase 2 ALTITUDE-AD study aims to evaluate the efficacy and safety of sabirnetug in slowing cognitive decline in early Alzheimer's patients, with 542 individuals enrolled [9] - Topline results from the ALTITUDE-AD study are expected in late 2026 [9]

Financial Data and Key Metrics Changes - As of September 30, 2025, the company had $136.1 million in cash and marketable securities, expected to support clinical and operational activities into early 2027 [10] - R&D expenses for Q3 2025 were $22 million, a decrease from the prior year primarily due to reduced CRO costs associated with the ALTITUDE-AD clinical trial [10] - G&A expenses were $4.5 million in Q3 2025, down due to reductions in legal fees, audit, and recruiting expenses [10] - The company reported a loss from operations and a net loss of $26.5 million for the quarter [11] Business Line Data and Key Metrics Changes - The ALTITUDE-AD trial is progressing with 542 participants enrolled, and some are beginning to complete the placebo-controlled phase [4][5] - The open-label extension of the trial allows participants to receive sabirnetug at 35 mg per kg every four weeks for up to 52 weeks, aimed at gathering long-term safety and efficacy data [5] Market Data and Key Metrics Changes - The company is exploring a strategic collaboration with JCR Pharmaceuticals to develop an Alzheimer's disease product that combines A-beta oligomer selective antibody expertise with blood-brain barrier technology [6][8] Company Strategy and Development Direction - The company is focused on advancing the ALTITUDE-AD trial and the Enhanced Brain Delivery (EBD) program, targeting synaptotoxic A-beta oligomers for Alzheimer's treatment [4][11] - The addition of Dr. George Golembeski to the board is expected to enhance strategic initiatives and business development efforts [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution of the ALTITUDE-AD trial and anticipates sharing top-line results in late 2026 [11] - The EBD program is seen as a potential next-generation product opportunity in Alzheimer's treatment [5][11] Other Important Information - The company plans to present data at upcoming medical conferences related to the EBD program [7] - A non-clinical data package, including a non-human primate study, is expected in early 2026 to inform decisions on advancing development candidates [8] Q&A Session Summary Question: What are the criteria for the early transferrin data for a go/no-go decision? - Management indicated that they are looking for a meaningful increase in overall exposure of sabirnetug in the brain, which could enhance efficacy and safety [15][16] Question: How does the Evoke trials impact the company's approach? - Management is monitoring the GLP-1 studies closely and believes that improved metabolic profiles could positively affect Alzheimer's patients [18] Question: Will both candidates in the shuttle program be advanced simultaneously? - It is too early to determine if one or both candidates will advance, as it will be data-dependent in early 2026 [36] Question: What biomarkers will be included in the non-clinical data package? - The data package will include preclinical studies on pharmacokinetics and biomarker profiles, including A-beta levels and synaptic markers [32][33] Question: What is the minimum expectation from the ALTITUDE-AD study? - The primary outcome will be assessed using the iADRS scale, and management is looking for a clear and demonstrable effect on clinical scales [40][42]